| Name | Title | Contact Details |
|---|
ActaCell is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.
Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases
Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.